Acalabrutinib (Calquence) accepted for restricted use within NHS Scotland for treatment of previously untreated chronic lymphocytic leukaemia (CLL)

Treatment is restricted to monotherapy for the treatment of adult patients with previously untreated CLL without a del(17p) or TP53 mutation and who are ineligible for fludarabine, cyclophosphamide and rituximab (FCR) therapy.

Source:

Scottish Medicines Consortium